Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)
| Status: | Terminated |
|---|---|
| Conditions: | Ovarian Cancer, Women's Studies, Infertility |
| Therapuetic Areas: | Oncology, Reproductive |
| Healthy: | No |
| Age Range: | 18 - 40 |
| Updated: | 5/17/2018 |
| Start Date: | March 2015 |
| End Date: | June 2016 |
Optimizing Fertility Treatment in Women With Polycystic Ovary Syndrome (PCOS) - A Randomized Controlled Trial: The Role of Progestin-induced Endometrial Shedding in PCOS (PIES in PCOS)
Progestin-induced endometrial shedding (PIES) followed by clomiphene citrate is fertility
treatment of choice in anovulatory women with polycystic ovary syndrome (PCOS). However, some
preliminary data suggest that skipping PIES could result in a higher live birth rate. The
investigators are performing the first randomized controlled trial to find out if skipping
the use of progestin during fertility treatment of anovulatory PCOS women is associated with
improved pregnancy and live birth rates compared to the traditional approach of using
progestin prior to use of clomiphene citrate.
treatment of choice in anovulatory women with polycystic ovary syndrome (PCOS). However, some
preliminary data suggest that skipping PIES could result in a higher live birth rate. The
investigators are performing the first randomized controlled trial to find out if skipping
the use of progestin during fertility treatment of anovulatory PCOS women is associated with
improved pregnancy and live birth rates compared to the traditional approach of using
progestin prior to use of clomiphene citrate.
This is a prospective randomized trial of clomiphene citrate (CC) preceded by
progestin-induced endometrial shedding (PIES) vs CC without PIES in the treatment of
infertility in patients with PCOS, for up to 5 treatment cycles.
Participants will be randomized to receive either progestin followed by CC starting on day 3
of the induced menses, or CC without induced menses. Study participants will be monitored at
regular 2 to 4 wks intervals for response to medication using ultrasound and hormonal
parameters. The maximum dose of CC will not exceed 750 mg/cycle. Treatment will not exceed 5
ovulatory cycles. Participants who are resistant to 150 mg of CC will exit the study.
170 anovulatory PCOS women actively seeking pregnancy, aged 18 through 40 years will be
enrolled and randomized in a 1:1 treatment ratio into the two study arms. Anovulation will be
the only infertility factor in all patients.
progestin-induced endometrial shedding (PIES) vs CC without PIES in the treatment of
infertility in patients with PCOS, for up to 5 treatment cycles.
Participants will be randomized to receive either progestin followed by CC starting on day 3
of the induced menses, or CC without induced menses. Study participants will be monitored at
regular 2 to 4 wks intervals for response to medication using ultrasound and hormonal
parameters. The maximum dose of CC will not exceed 750 mg/cycle. Treatment will not exceed 5
ovulatory cycles. Participants who are resistant to 150 mg of CC will exit the study.
170 anovulatory PCOS women actively seeking pregnancy, aged 18 through 40 years will be
enrolled and randomized in a 1:1 treatment ratio into the two study arms. Anovulation will be
the only infertility factor in all patients.
Inclusion
- Women aged 18 - 40, desiring pregnancy
- Established diagnosis of PCOS confirmed by the Rotterdam criteria
- Oligo or anovulatory, with menstrual cycles > 35 days apart or less than 9 menstrual
cycles per year
- Normal vaginal ultrasound with endometrial stripe < 12 mm
- Normal thyroid stimulating hormone (TSH) within past one year
- Normal prolactin (PRL) within past one year
- For women with previous successful Clomid treatment, a washout period of at least 2
months is required
Exclusion
- Regular menstrual cycles occurring less than 35 days apart
- Evidence of other infertility factors such as endometriosis, tubal factor or male
infertility
- Prior unsuccessful Clomiphene citrate ovulation cycles
- Abnormal vaginal ultrasound findings such as endometrial polyps, submucous myomas,
synechiae
- Uterine anomaly such as unicornuate or bicornuate uterus
- Presence of hydrosalpinx
- Evidence of active endocrinopathy, such as thyroid disorder or hyperprolactinemia
- Partner with abnormal semen analysis (count < 15 million sperm /ml)
We found this trial at
1
site
2035 W Taylor St
Chicago, Illinois
Chicago, Illinois
(312) 996-4350
Principal Investigator: Albert Asante, MD, MPH
Phone: 312-355-4983
University of Illinois at Chicago A major research university in the heart of one of...
Click here to add this to my saved trials
